Do 18 F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?

Ayse Tuba Kendi, Kelly Magliocca, Amanda Corey, Dana C. Nickleach, James Galt, Kristin Higgins, Jonathan J. Beitler, Mark W. El-Deiry, J. Trad Wadsworth, Patricia A. Hudgins, Nabil F. Saba, David M. Schuster

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVE: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). PATIENTS AND METHODS: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV-) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. RESULTS: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV- group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). CONCLUSIONS: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.

Original languageEnglish (US)
Pages (from-to)e196-e200
JournalClinical nuclear medicine
Volume40
Issue number3
DOIs
StatePublished - Mar 13 2015
Externally publishedYes

Fingerprint

Mouth
Squamous Cell Carcinoma
Odds Ratio
Glycolysis
Tumor Burden
Logistic Models
Oropharyngeal Neoplasms
Mouth Neoplasms
ROC Curve

Keywords

  • F-FDG
  • head and neck carcinoma
  • human papillomavirus
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Do 18 F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? . / Tuba Kendi, Ayse; Magliocca, Kelly; Corey, Amanda; Nickleach, Dana C.; Galt, James; Higgins, Kristin; Beitler, Jonathan J.; El-Deiry, Mark W.; Wadsworth, J. Trad; Hudgins, Patricia A.; Saba, Nabil F.; Schuster, David M.

In: Clinical nuclear medicine, Vol. 40, No. 3, 13.03.2015, p. e196-e200.

Research output: Contribution to journalArticle

Tuba Kendi, A, Magliocca, K, Corey, A, Nickleach, DC, Galt, J, Higgins, K, Beitler, JJ, El-Deiry, MW, Wadsworth, JT, Hudgins, PA, Saba, NF & Schuster, DM 2015, ' Do 18 F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? ', Clinical nuclear medicine, vol. 40, no. 3, pp. e196-e200. https://doi.org/10.1097/RLU.0000000000000691
Tuba Kendi, Ayse ; Magliocca, Kelly ; Corey, Amanda ; Nickleach, Dana C. ; Galt, James ; Higgins, Kristin ; Beitler, Jonathan J. ; El-Deiry, Mark W. ; Wadsworth, J. Trad ; Hudgins, Patricia A. ; Saba, Nabil F. ; Schuster, David M. / Do 18 F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? In: Clinical nuclear medicine. 2015 ; Vol. 40, No. 3. pp. e196-e200.
@article{11b94d2a1a6948208574753a12869155,
title = "Do 18 F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?",
abstract = "OBJECTIVE: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). PATIENTS AND METHODS: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV-) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. RESULTS: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV- group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94{\%} vs 43{\%}; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). CONCLUSIONS: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.",
keywords = "F-FDG, head and neck carcinoma, human papillomavirus, PET",
author = "{Tuba Kendi}, Ayse and Kelly Magliocca and Amanda Corey and Nickleach, {Dana C.} and James Galt and Kristin Higgins and Beitler, {Jonathan J.} and El-Deiry, {Mark W.} and Wadsworth, {J. Trad} and Hudgins, {Patricia A.} and Saba, {Nabil F.} and Schuster, {David M.}",
year = "2015",
month = "3",
day = "13",
doi = "10.1097/RLU.0000000000000691",
language = "English (US)",
volume = "40",
pages = "e196--e200",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Do 18 F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?

AU - Tuba Kendi, Ayse

AU - Magliocca, Kelly

AU - Corey, Amanda

AU - Nickleach, Dana C.

AU - Galt, James

AU - Higgins, Kristin

AU - Beitler, Jonathan J.

AU - El-Deiry, Mark W.

AU - Wadsworth, J. Trad

AU - Hudgins, Patricia A.

AU - Saba, Nabil F.

AU - Schuster, David M.

PY - 2015/3/13

Y1 - 2015/3/13

N2 - OBJECTIVE: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). PATIENTS AND METHODS: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV-) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. RESULTS: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV- group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). CONCLUSIONS: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.

AB - OBJECTIVE: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). PATIENTS AND METHODS: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV-) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. RESULTS: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV- group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). CONCLUSIONS: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.

KW - F-FDG

KW - head and neck carcinoma

KW - human papillomavirus

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84922670894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922670894&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000691

DO - 10.1097/RLU.0000000000000691

M3 - Article

C2 - 25608156

AN - SCOPUS:84922670894

VL - 40

SP - e196-e200

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 3

ER -